IXICO CEO on strong 2025 performance, 2026 priorities
Update: 2025-10-16
Description
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strong performance in 2025, highlighting above-guidance revenue delivery and continued progress in its strategic focus areas. Goorden detailed how the 'Innovate, Lead, Scale' strategy has driven growth, with three core pillars: new contract wins, contract extensions, and expansion into new verticals such as blood-based biomarkers.
Discussing full-year trading, Goorden noted a boost in new contracts, particularly within neurology and Alzheimer’s disease, aligning with IXICO’s strategic goals. He emphasised that “we start to now also see that, especially for Alzheimer's disease in revenue.”
Contract extensions also played a significant role, including one in a major Alzheimer’s program. Additionally, IXICO’s movement into validating diagnostic blood tests was underlined by a new deal in this space, further building on earlier work with companies like Fujirebio.
Goorden addressed the effective use of capital raised in the prior year, confirming investments in innovation, personnel, and US operational scale-up were all “on track” and have now moved into the execution phase.
Looking ahead to 2026, the company aims to maintain its trajectory and highlight innovations more publicly, potentially exploring new partnerships.
For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications.
#IXICO #Biomarkers #Neurology #AlzheimersResearch #BloodBiomarkers #BiotechNews #ClinicalTrials #DiagnosticValidation #HealthcareTech #InvestorUpdates
Discussing full-year trading, Goorden noted a boost in new contracts, particularly within neurology and Alzheimer’s disease, aligning with IXICO’s strategic goals. He emphasised that “we start to now also see that, especially for Alzheimer's disease in revenue.”
Contract extensions also played a significant role, including one in a major Alzheimer’s program. Additionally, IXICO’s movement into validating diagnostic blood tests was underlined by a new deal in this space, further building on earlier work with companies like Fujirebio.
Goorden addressed the effective use of capital raised in the prior year, confirming investments in innovation, personnel, and US operational scale-up were all “on track” and have now moved into the execution phase.
Looking ahead to 2026, the company aims to maintain its trajectory and highlight innovations more publicly, potentially exploring new partnerships.
For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications.
#IXICO #Biomarkers #Neurology #AlzheimersResearch #BloodBiomarkers #BiotechNews #ClinicalTrials #DiagnosticValidation #HealthcareTech #InvestorUpdates
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
